Modulation of plasma uridine concentration by 5- (phenylselenenyl)acyclouridine, an inhibitor of uridine phosphorylase: Relevance to chemotherapy

Cancer Chemotherapy and Pharmacology

Volumn 45, Issue 5, 2000, Pages 351-361

  Ashour, Osama M ^a,b   Al Safarjalani, Omar N ^b   Naguib, Fardos N M ^b   Goudgaon, Naganna M ^c,d   Schinazi, Raymond F ^c,d   El Kouni, Mahmoud H ^b  

^a MINIA UNIVERSITY   (Egypt)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c ATLANTA VA MEDICAL CENTER   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

5 (Phenylselenenyl)acyclouridine; Chemotherapy; Uridine phosphorylase

Indexed keywords

5 (PHENYLSELENENYL)ACYCLOURIDINE; UNCLASSIFIED DRUG; URACIL; URIDINE; URIDINE PHOSPHORYLASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; MEAN RESIDENCE TIME; MOUSE; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY;

EID: 0034101695     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800051002     Document Type: Article

References (81)

1. 1. Ashour OM, Naguib FNM, el Kouni MH (1996) 5-(m-Benzyloxybenzyl)barbituric acid acyclonucleoside, a uridine phosphorylase inhibitor and 2′,3′,5′-tri-o-acetyluridine, a pro-drug of uridine as modulators of plasma uridine concentration: implication for chemotherapy. Biochem Pharmacol 51: 1601
2. 2. Aussedat J (1983) Effect of uridine supply on glycogen resynthesis after ischaemia in the isolated perfused rat heart. Cardiovasc Res 17: 145
3. 3. Aussedat J (1984) Uridine incorporation in normal and ischaemic perfused rat heart. Mol Physiol 6: 247
4. 4. Aussedat J, Verdetti J, Grably S, Rossi A (1982) Nucleotides uridyliques et glycogene cardiaque: effect de l'administration d'uridine et de ribose chez le rat. J Physiol (Paris) 78: 331
5. 5. Bonavita B, Zito M (1968) Analisi dell'azione di nucleosidi pirimidinici sull'elettroencefallogramma umano attivato con megimide. Riv Neurol 38: 317
6. 6. Bonavita V, Monaco P, Tripi E (1964) Analisi degli effetti centrali di nucleotidi purinici e pirinmidinici e loro derivati III. Esperimenti farmacologici. Acta Neurol (Napoli) 19: 215
7. 7. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248
8. 8. Buckley NM, Tsuboi KK, Zeic NJ (1959) Effects of nucleosides on acute left ventricular failure in isolated dog heart. Circ Res 7: 847
9. 9. Bushma MI, Parkhovchenko EI, Peschanskii VS (1980) Effects of cytidine and uridine on the regeneration of the liver in rats poisoned with carbon tetrachloride. Bull Exp Biol Med 88: 722
10. 10. Chan TCK, Markman M, Pfeifle CE, Taetle R, Abramson I, Howell SB (1988) Uridine pharmacokinetics in cancer patients. Cancer Chemother Pharmacol 22: 83
11. 11. Cherwinski HM, Byars N, Ballaron SJ, Nakano GM, Young JM, Ransom JT (1995) Leflunomide interferes with pyrimidine nucleotide biosynthesis. Inflamm Res 44: 317
12. 12. Cradock JC, Vishnuvajjala BR, Chin TF, Hochstein HD, Ackerman SK (1986) Uridine-induced hyperthermia in the rabbit. J Pharm Pharmacol 38: 226
13. 13. Darnowski JW, Handschumacher RE (1985) Tissue-specific enhancement of uridine utilization and 5-fluorouracil therapy in mice by benzylacyclouridine. Cancer Res 45: 5364
14. 14. Darnowski JW, Handschumacher RE (1986) Tissue uridine pools: evidence in vivo of a concentrative mechanism for uridine uptake. Cancer Res 46: 3490
15. 15. Darnowski JW, Handschumacher RE (1988) Benzylacyclouridine: pharmacokinetics, metabolism and biochemical effects in mice. Biochem Pharmacol 37: 2613
16. 16. Darnowski JW, Handschumacher RE (1989) Enhancement of fluorouracil therapy by the manipulation of tissue uridine pools. Pharmacol Ther 41: 381
17. 17. Darnowski JW, Handschumacher RE, Wiegand RA, Goulette FA, Calabresi P (1991) Tissue-specific expansion of uridine pools in mice. Effects of benzylacyclouridine, dipyridamole and exogenous uridine. Biochem Pharmacol 41: 2031
18. 18. Davis ST, Joyner SS, Chandrasurin P, Baccanari DP (1993) Species-dependent differences in the biochemical effects and metabolism of 5-benzylacyclouridine. Biochem Pharmacol 45: 173
19. 19. Dwivedi C, Harbison RD (1975) Anticonvulsant activities of Δ-8 and Δ-9 tetrahydrocannabinol and uridine. Toxicol Appl Pharmacol 31: 452
20. 20. el Kouni MH, Naguib FNM, Park KS, Cha S, Darnowski JW, Soong S-J (1990) Circadian rhythm of hepatic uridine phosphorylase activity and plasma concentration of uridine in mice. Biochem Pharmacol 40: 2479
21. 21. el Kouni MH, el Kouni MM, Naguib FNM (1993) Differences in activities and substrate specificity of human and murine pyrimidine nucleoside phosphorylases: implications for chemotherapy with 5-fluoropyrimidines. Cancer Res 53: 3687
22. 22. Elrick H, Hlad CJ Jr, Arai Y (1962) Influence of certain nucleosides on glucose metabolism in man. Metabolism 11: 46
23. 23. Falcone A, Darnowski JW, Ruprecht RM, Chu SH, Burnetti I, Calabresi P (1990) Differential effect of benzylacyclouridine on the toxic and therapeutic effects of azidothymidine in mice. Blood 76: 2216
24. 24. Gallai V, Mazzotta G, Montesi S, Sarchielli P, Del Gatto F (1992) Effects of uridine in the treatment of diabetic neuropathy: an electrophysiological study. Acta Neurol Scand 86: 3
25. 25. Gasser T, Moyer JD, Handschumacher RE (1981) Novel single-pass exchange of circulating uridine in rat liver. Science 213: 777
26. 26. Geiger A, Yamasaki S (1956) Cytidine and uridine requirement of the brain. J Neurochem 1: 93
27. 27. Gomeni R, Gomeni C (1978) Interactive graphic package for pharmacokinetic analysis. Com Biomed Res 11: 345
28. 28. Goudgaon NM, Naguib FNM, el Kouni MH, Schinazi RF (1993) Phenylselenenyl-and phenylthio-substituted pyrimidines as potential inhibitors of dihydrouracil dehydrogenase and uridine phosphorylase. J Med Chem 36: 4250
29. 29. Greene S, Watanabe K, Braatz-Trulson J, Lou L (1995) Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent, leflunomide. Biochem Pharmacol 50: 861
30. 30. Grem JL (1990) Fluorinated pyrimidines. In: Chabner BA, Collins JM (eds) Cancer chemotherapy; principles and practice. Lippincott, Philadelphia, p 180
31. 31. Guarneri P, Guarner R, Mocciaro C, Piccoli F (1983) Interaction of uridine with GABA binding sites in cerebellar membranes of the rat. Neurochem Res 8: 1537
32. 32. Guarneri P, Guarner R, Mocciaro C, Piccoli F (1985) Interaction of uridine with GABA-mediated inhibitory transmission: studies in vivo and in vitro. Epilepsia 26: 666
33. 33. Holstege A, Leser, H-G, Pausch J, Gerok W (1985) Uridine catabolism in Kupffer cells, endothelial cells, and hepatocytes, Eur J Biochem 149: 169
34. 34. Holstege A, Pausch J, Gerok W (1986) Effect of 5-diazouracil on the catabolism of circulating pyrimidines in rat liver and kidneys. Cancer Res 46: 5576
35. 35. Inoué S (1993) Sleep-promoting substance (SPS) and physiological sleep regulation. Zool Sci 10: 557
36. 36. Jann G, Delzanno GB (1969) Azione della citidina ed uridina nel trattamento delle indromi neuropsichiche da encefalopatie di varia origine. Minerva Med 60: 2092
37. 37. Keilbauch SA, Hobbs GA, Simpson MV (1993) Anti-human immunodeficiency virus type 1 therapy and peripheral neuropathy: prevention of 2′,3′-dideoxycytidine toxicity in PC12 cells, a neuronal model by uridine and pyruvate. Mol Pharmacol 44: 702
38. 38. Kelly WN, Smith LH Jr (1978) Hereditary orotic aciduria. In: Stanbury JB, Wyngaarden JB, Fredrickson DS (eds) The metabolic basis of inherited disease, 4th edn. McGraw-Hill, New York, p 1045
39. 39. Klubes P, Cerna I (1983) Use of uridine rescue to enhance the antitumor selectivity of 5-fluorouracil. Cancer Res 43: 3182
40. 40. Klubes P, Cerna I, Meldon MA (1982) Uridine rescue from the lethal toxicity of 5-fluorouracil in mice. Cancer Chemother Pharmacol 8: 17
41. 41. Klubes P, Geffen DB, Cysyk RL (1986) Comparison of the bioavailability of uridine in mice after either oral or parenteral administration. Cancer Chemother Pharmacol 17: 236
42. 42. Kypson J, Hait G (1976) Effects of uridine and inosine on glucose metabolism in skeletal muscle and activated lipolysis in adipose tissue. J Pharmacol Exp Ther 199: 565
43. 43. Kypson J, Hait G (1977) Metabolic effects of inosine and uridine in rabbit hearts and rat skeletal muscles. Biochem Pharmacol 26: 1585
44. 44. Kypson J, Hait G, Mathew R (1978) Effects of uridine on the performance and the metabolism of oxygenated and hypoxic rabbit hearts. J Mol Cell Cardiol 10: 545
45. 45. Leyva A, van Groeningen CJ, Kraal I, Peters GJ, Lankelma J, Pinedo HM (1984) Phase I and pharmacokinetic studies of high-dose uridine intended for rescue from 5-fluorouracil toxicity. Cancer Res 44: 5928
46. 46. Marquardt DW (1963) An algorithm for least squares estimation of nonlinear parameters. J Soc Ind Appl Math 11: 431
47. 47. Martin DS, Stolfi RL, Sawyer RC, Spiegelman S, Young CW (1982) High-dose 5-fluorouracil with delayed uridine "rescue" in mice. Cancer Res 42: 3964
48. 48. Martin DS, Stolfi RL, Sawyer RC (1989) Use of oral uridine as a substitute for parental uridine rescue of 5-fluorouracil therapy, with and without the uridine phosphorylase inhibitor 5-benzylacyclouridine. Cancer Chemother Pharmacol 24: 9
49. 49. Meerson FZ, Dosmagabetova RS (1985) The use of glucose and uridine to control contractility and extensibility disturbances in the nonischemized compartments of the heart in myocardial infarction. Kardiologiya 25: 91
50. 50. Monks A, Cysyk RL (1982) Uridine regulation by the isolated rat liver: perfusion with an artificial oxygen carrier. Am J Physiol 242: R465
51. 51. Monks A, Ayers O, Cysyk RL (1983) Effect of 5-benzylacyclouridine, a potent inhibitor of uridine phosphorylase, on the metabolism of circulating uridine by the isolated rat liver. Biochem Pharmacol 32: 2003
52. 52. Monticone GF, Bergamasco B, Congnazzo A (1966) Sull'impiego terapeutico dei nucleosidi citidina ed uridina in alcune affezioni neurologiche. Minerva Med 57: 4348
53. 53. Moyer JD, Oliver JT, Handschumacher RE (1981) Salvage of circulating pyrimidine nucleosides in the rat. Cancer Res 41: 3010
54. 54. Myers CS, Napolitano M, Fisher H, Wagner GC (1993) Uridine and stimulant-induced motor activity. Proc Soc Exp Biol Med 204: 49
55. 55. Myers CS, Fisher H, Wagner GC (1994) Uridine potentiates haloperidol's disruption of conditioned avoidance responding. Brain Res 651: 194
56. 56. Naguib FNM, el Kouni MH, Cha S (1985) Enzymes of uracil catabolism in normal and neoplastic human tissues. Cancer Res 45: 5405
57. 57. Naguib FNM, el Kouni MH, Chu SH, Cha S (1987) New analogues of benzylacyclouridines, specific and potent inhibitors of uridine phosphorylase from human and mouse livers. Biochem Pharmacol 36: 2195
58. 58. Naguib FNM, Soong S-J, el Kouni MH (1993) Circadian rhythm of orotate phosphoribosyltransferase, pyrimidine nucleoside phosphorylases and dihydrouracil dehydrogenase in mouse liver: possible relevance to chemotherapy with 5-fluoropyrimidines. Biochem Pharmacol 45: 667
59. 59. Nair RV, Cao W, Morris RE (1995) Inhibition of smooth muscle cell proliferation in vitro by leflunomide, a new immunosuppressant, is antagonized by uridine. Immunol Lett 48: 77
60. 60. Niedzwicki JG, Chu SH, el Kouni MH, Rowe EC, Cha S (1982) 5-Benzylacyclouridine and 5-benzyloxybenzylacyclouridine, potent inhibitors of uridine phosphorylase. Biochem Pharmacol 31: 1857
61. 61. Page T, Yu A, Fontanesi J, Nyhan WL (1997) Developmental disorder associated with increased cellular nucleotidase activity. Proc Natl Acad Sci USA 94: 11601
62. 62. Peters GJ, van Groeningen CJ (1991) Clinical relevance of biochemical modulation of 5-fluorouracil. Ann Oncol 2: 469
63. 63. Peters GJ, van Groeningen CJ, Laurensse EJ, Lankelma J, Kraal I, Leyva A, Lankelma J, Pinedo HM (1987a) Effect of pyrimidine nucleosides on body temperatures of man and rabbit in relation to pharmacokinetic data. Pharm Res 4: 113
64. 64. Peters GJ, van Groeningen CJ, Laurensse E, Levya A, Pinedo HM (1987b) Uridine-induced hypothermia in mice and rats in relation to plasma and tissue levels of uridine and its metabolites. Cancer Chemother Pharmacol 20: 101
65. 65. Peters GJ, van Dijk J, Laurensse E, van Groeningen CJ, Lankelman J, Levya A. Nadal JC, Pinedo HM (1988) In vitro biochemical and in vivo biological studies of the uridine "rescue" of 5-fluorouracil. Br J Cancer 57: 259
66. 66. Pizzorno G, Yee L, Burtness BA, Marsh JC, Darnowski JW, Chu MYW, Chu HS, Chu E, Leffert JJ, Handschumacher RE, Calabresi P (1998) Phase I clinical and pharmacological studies of benzylacyclouridine, a uridine phosphorylase inhibitor. Clin Cancer Res 4: 1165
67. 67. Roberts CA (1973) Anticonvulsant effects of uridine: comparative analysis of Metrazol and penicillin induced foci. Brain Res 55: 291
68. 68. Roberts CA, Kreisman NR, Waltman M (1974) Uridine anticonvulsant effects: selective control of nucleoside incorporation in experimental epilepsy. Epilepsia 15: 479
69. 69. Sanguineti I, Zerbi D (1965) L'impiego di alcuni nucleosidi non vasoattivi (citidina e uridina) nella terapia delle vasculopatie cerebrali. Minerva Med 56: 3352
70. 70. Seiter K, Kemeny N, Martin D, Schneider A, Williams L, Colofiore J, Sawyer R (1993) Uridine allows dose escalation of 5-fluorouracil when given with N-phosphoancetyl-l-aspartate, methotrexate, and leucovorin. Cancer 71: 1875
71. 71. Sepe O (1970) Efficacia dell'assoiazione citidina-uridina nelle affezioni vascolari dell'encefalo. Minerva Med 61: 5934
72. 72. Sommadossi J-P, Carlisle R, Schinazi RF, Zhou Z (1988) Uridine reverses the toxicity of 3′-azido-3′-deoxythymidine in normal human granulocyte-macrophage progenitor cells in vitro without impairment of antiretroviral activity. Antimicrob Agents Chemother 32: 997
73. 73. Sommadossi J-P, Zhu Z, Carlisle R, Xie MY, Weidner DA, el Kouni MH (1990) Novel pharmacologie approaches for the treatment of AIDS and potential use of uridine phosphorylase inhibitors In: Diasio RB, Sommadossi J-P (eds) Advances in chemotherapy of AIDS. Pergamon Press, New York, p 63
74. 74. Sommadossi J-P, Cretton EM, Kidd LB, McClure HM, Anderson DC, el Kouni MH (1995) Effects of 5-benzylacyclouridine, an inhibitor of uridine phosphorylase, on the pharmacokinetics of uridine in rhesus monkeys: implications for chemotherapy. Cancer Chemother Pharmacol 37: 14
75. 75. Songu E, Haugaard ES, Wildley G, Haugaard N (1980) The relationship between uracil nucleotide concentrations and glycogen synthesis in hepatocytes from fed and fasted rats. Metabolism 30: 119
76. 76. Tamura K, Woo J, Bakri MT, Thomson AW (1993) Brequinar sodium inhibits interleukin-6-induced differentiation of a human B-cell line into IgM-secreting plasma cells. Immunology 79: 587
77. 77. van Groeningen CJ, Leyva A, Kraal I, Peters GJ, Pinedo HM (1986) Clinical and pharmacokinetic studies of prolonged administration of high-dose uridine intended for rescue from 5-FU toxicity. Cancer Treat Rep 70: 745
78. 78. van Groeningen CJ, Peters GJ, Leyva A, Laurensse E, Pinedo HM (1989) Reversal of 5-fluorouracil induced myelosuppression by prolonged administration of high-dose uridine. J Natl Cancer Inst 81: 157
79. 79. van Groeningen CJ, Peters GJ, Nadal JC, Leyva A, Laurensse E, Pinedo HM (1991) Clinical and pharmacologic study of orally administered uridine. J Natl Cancer Inst 83: 437
80. 80. van Groeningen CJ, Peters GJ, Pinedo HM (1992) Modulation of fluorouracil toxicity with uridine. Semin Oncol 19: 148
81. 81. Williamson RA, Yea CM, Robson PA, Curnock AP, Gadher S, Hambleton AB, Woodward K, Bruneau J-M, Hambleton P, Moss D, Thomson TA, Spinella-Jaegle S, Morand P, Courtin O, Sautés C, Westwood R, Hercend T, Kuo EA, Ruuth E (1995) Dihydroorotate dehydrogenase is a high affinity binding protein for A77 1726 and mediator of a range of biological effects of the immunomodulatory compound. J Biol Chem 270: 22467